

HoxB13 is a **transcription factor** defining posterior endodermal derivatives, including **prostate** and **rectum**. While it is used as a **marker** of **prostate cancer**, it has not been studied systematically in **neuroendocrine neoplasms**. Thus, Soukup et al. performed HoxB13 **immunohistochemistry** in **tissue microarrays** and the whole sections of 232 neuroendocrine neoplasms. These included 34 **paragangliomas** (PGs), 20 cauda equina **neuroendocrine tumors** (CENETs), 123 **well-differentiated neuroendocrine tumors** (WDNETs), and 55 neuroendocrine carcinomas (NECs). WDNETs were additionally analyzed with SATB2 and colorectal WDNETs with CDX2 and serotonin immunohistochemistry. In total, HoxB13 immunoreactivity was observed in 95% (19/20) CENETs, 10.6% (13/123) WDNETs, and 12.9% (7/54) NECs. No PGs were positive. Large intestine WDNETs expressed HoxB13 in 68.4% (13/19); five negative tumors originated in the cecum and one in the rectum. In rectum, 92.9% (13/14) WDNETs expressed HoxB13. HoxB13 was 92.9% sensitive and 100% specific, showing a 100% positive predictive value for the rectal origin of WDNET. In NECs, HoxB13 was positive in 15.4% (2/13) GIT tumors and 80% (4/5) prostatic NECs, but in none of the urinary bladder NECs (0/8). SATB2 was positive in 17.1% (21/123) WDNETs, including 78.9% (15/19) of colorectal WDNETs, 71.4% (5/7) appendiceal WDNETs, and 2.9% (1/34) small intestine WDNETs. All 4 SATB2-negative large bowel tumors originated in the cecum. When both markers combined, HoxB13+/SATB2+ immune profile was seen exclusively in rectal WDNETs (positive predictive value 100%), while HoxB13-/SATB2+ immune profile was highly suggestive of the appendiceal origin (positive predictive value 71.4%). Therefore, HoxB13 can be useful as an immunohistochemical marker of rectal WDNETs and prostatic NECs ¹⁾.

¹⁾

Soukup J, Manethova M, Stejskal V, Hornychova H, Cesak T, Netuka D, Ryska A, Gabalec F. Immunoreactivity of HOXB13 in Neuroendocrine Neoplasms Is a Sensitive and Specific Marker of Rectal Well-Differentiated Neuroendocrine Tumors. *Endocr Pathol*. 2023 Aug 8. doi: 10.1007/s12022-023-09779-9. Epub ahead of print. PMID: 37552455.

From:

<https://neurosurgerywiki.com/wiki/> - **Neurosurgery Wiki**

Permanent link:

https://neurosurgerywiki.com/wiki/doku.php?id=well-differentiated_neuroendocrine_tumor

Last update: **2024/06/07 02:57**

